IADR Abstract Archives

Clinical Efficacy of Four Experimental Toothpastes on Gloss and Smoothness

Objectives: To evaluate the effects of four experimental toothpastes with a novel alumina abrasive system and sodium tripolyphosphate (STP) on tooth gloss and smoothness compared to standard toothpaste after one and four weeks of twice daily use.

Methods:

This was a single centre, single (examiner) blind, randomised, five-group parallel study in healthy volunteers. 291 subjects were evaluated for tooth gloss (Sturzenberger's Gloss Index) and smoothness (hygienist tactile, clinical evaluation of smoothness) at Baseline, Week 1 and Week 4.

At baseline subjects were randomised to one of five toothpaste treatments (1.5% w/w Alumina and 7.5% w/w STP or 5% w/w STP, 1% w/w Alumina and 7.5% w/w STP or 5% w/w STP, and Aquafresh Advanced), after which subjects received a dental prophylaxis.

Subjects brushed twice daily at home with their allocated treatment for 4 weeks.

 

Results:

Table: Summary of change from baseline in Gloss and Smoothness (ITT population)

Variable

Week

1.5% Alumina and 7.5% STP

1.5% Alumina and 5% STP

1% Alumina and 7.5% STP

1% Alumina and 5% STP

Aquafresh Advanced

 

 

Adjusted Mean (SE) (p-value)

Adjusted Mean (SE) (p-value)

Adjusted Mean (SE) (p-value)

Adjusted Mean (SE) (p-value)

Adjusted Mean (SE) (p-value)

Gloss

4

0.77(0.073)

<0.0001

0.82(0.071)

<0.0001

0.81(0.071)

<0.0001

0.69(0.073)

<0.0001

0.29(0.072)

<0.0001

Smoothness

4

-0.26(0.045)

<0.0001

-0.29(0.045)

<0.0001

-0.31(0.044)

<0.0001

-0.28(0.047)

<0.0001

-0.14(0.044)

0.0015

All the experimental formulations produced statistically significantly greater changes to gloss and smoothness as compared to baseline and to Aquafresh Advanced at both Weeks 1 and 4 ( p <0.05).  All test products were well tolerated.

Conclusion: All experimental formulations demonstrated better efficacy on gloss and smoothness as compared to a standard silica toothpaste.

 


IADR/AADR/CADR General Session
2011 IADR/AADR/CADR General Session (San Diego, California)
San Diego, California
2011
3585
Pharmacology, Therapeutics, & Toxicology
  • Bordas, Alice  ( GlaxoSmithKline CHRD, Weybridge, N/A, United Kingdom )
  • Bosma, Marylynn  ( GlaxoSmithKline CHRD, Weybridge, N/A, United Kingdom )
  • Milleman, Kimberly R.  ( University Park Research Center, Fort Wayne, IN, USA )
  • Kleber, Carl  ( University Park Research Center, Ft Wayne, IN, USA )
  • Kulkarni, Harshad  ( GlaxoSmithKline CHRD, Gurgaon, N/A, India )
  • Fleming, Nancy  ( GlaxoSmithKline, CHRD, Parsippany, NJ, USA )
  • Poster Session
    Pharmacology, Therapeutics, & Toxicology II
    03/19/2011